Zestra Laboratories Elects New Board of Directors

Zestra Laboratories, Inc., global innovator in clinically proven intimacy products for women’s sexual health, announces the election of four new members to its board of directors, bringing the current number of board members to five. Its flagship product, Zestra® is available at more than 41,000 drugstore and retail outlets in the United States. It is the only women's topical intimacy product that is clinically proven to increase female sexual arousal, pleasure, desire/libido and satisfying sexual experiences for women; everything else available for women are simply lubricants. To date, there are still no FDA-approved prescription drug treatments for any form of female sexual dysfunction (FSD).

“We are gratified with the addition of our new directors, who bring extensive experience and serial successes in both prescription pharmaceuticals and consumer product brands to our Board,” Martin Crosby, Founder and Acting CEO of Zestra, said. “Their proven track records and their industry knowledge, business insights, and capital formation expertise will be invaluable to Zestra, as we accelerate our growth in 2008 and beyond.”

In 2008, Zestra plans to extend its product line in women’s health, introduce a male sexual health product, and increase its market penetration in Europe and Asia.

The 2008 Board of Directors took office on February 27, 2008. The board of directors includes: Anthony A. Rascio; Jay Popli; Reed Bolton Byrum; Martin Crosby, and Gerald Pribanic.

Anthony A. Rascio - Rascio was most recently Senior Vice President and Corporate Secretary of Esprit Pharma, a pharmaceutical company focused on the genitourinary (GU) and women’s healthcare markets. Rascio was instrumental in Esprit Pharma successfully completing a Series B funding round, raising $90 million in financing from a group of leading venture capital and private equity investors. Allergan (NYSE: AGN) acquired Esprit Pharma in a $370 million all-cash transaction in October 2007. Rascio formerly served as Senior Vice President and General Counsel for ESP Pharma where he was responsible for acquisitions, licensing, financing, patent, trademark, and copyright matters. He was instrumental in the sale of ESP Pharma to PDL Biopharma, Inc (NASDAQ: PDLI). Before that, he was Vice President and General Counsel of Roberts Pharmaceutical Corporation where he counseled the company in raising capital in excess of $400 million, negotiated multi-million dollar licensing arrangements with US, European, and Japanese companies, and helped lead the merger with Shire Pharmaceuticals of London (LSE: SHPGY). Earlier in his career, Rascio served as Legal Director, International Division, for Schering-Plough. Rascio received his undergraduate and J.D. degrees from Fordham University.

Jay Popli - Popli has more than 13 years experience creating and conducting pharmaceutical and consumer product marketing and advertising programs directed to healthcare professionals along with direct-to-consumer marketing campaigns. Currently Popli is Executive Vice President of Hygeia Therapeutics (formerly Orcas Therapeutics). Before joining Hygeia Therapeutics, Popli was Senior Director of Marketing at Sepracor (NASDAQ: SEPR), where he led the consumer marketing efforts for Lunesta®, a popular prescription sleep aid. Lunesta captured a 14 percent share of the market in only nine months and ranks as the seventh fastest launch in US pharmaceutical history. BrandWeek recognized Popli as one of its two Marketers of the Year in 2006 for his work in launching Lunesta. Before joining Sepracor, Popli held key positions at Novartis Consumer Health and at Procter and Gamble. While at Novartis he helped launch key products within the Maalox® and Lamisil® franchises. At Procter and Gamble he helped develop the initial positioning and launch plans for Actonel®, a multi-billion dollar osteoporosis medication. Popli holds a BS in Optics and an MBA from the University of Rochester.

Reed Bolton Byrum, APR, Fellow-PRSA – Byrum, Chairman of the Byrum Innovation Group, is a leading corporate strategist and consultant in the areas of strategic marketing, financial and public relations. Byrum served as a corporate executive for a variety of companies from Silicon Valley startups to Fortune 100 members EDS and GE Capital. He is the former President and CEO of the 29,000-member Public Relations Society of America, the world’s largest professional society for the public relations profession. Byrum, who has been recognized by PR Week as one of the top public relations executives in high technology, is President of the South Carolina Public Relations Society of America. He has served on numerous national and regional nonprofit boards and foundations. Byrum was an award-winning newspaper journalist and a director for Gannett during the introduction of USA TODAY. A graduate of Washington and Lee University, Byrum has taught a senior seminar in strategic communications at the University of Texas at Austin and has served on the President’s Staff of The Johns Hopkins University.

Gerald (Jerry) Pribanic, CMA - Pribanic is the Acting CFO of Zestra Laboratories and a Partner in the South Carolina practice of Tatum LLC. Pribanic has more than 30 years of multi-industry experience, including Pharmaceuticals, Consumer Products, Automotive, Plastics, Chemicals, Textiles, and Banking at the Board level. Before joining Tatum, Pribanic was Senior Vice President and Chief Financial Officer for Milliken and Company, an industry-leading textile and chemicals company manufacturer. From 1996-2000, Pribanic was the Executive Vice President and Chief Financial Officer of Maytag Corporation, the home and commercial appliance company. During the period 1990-1995, he served as the Vice President of Finance and Controller for Hoover Company, the vacuum cleaner icon. Pribanic received a BS in Accounting from The Pennsylvania State University and an MBA (Magna Cum Laude) from Fairleigh Dickinson University. Pribanic is a Certified Management Accountant.

Martin G. Crosby - Crosby is the founder, Chief Science Officer, and Acting CEO of Zestra Laboratories, Inc., a Delaware Corporation. Crosby is the inventor and developer of Zestra® (U.S. Patent 6,737,084 issued May 18th, 2004 and EU Patent EP1328281) with patent rights assigned to Zestra Laboratories, Inc. In 1993, Crosby founded Pharmaceutical Marketing Alliance (PMA), a nationwide pharmaceutical healthcare provider specializing in the disease management of Multiple Sclerosis (MS) patients receiving newly approved drugs for this neurologic condition. PMA was acquired by a publicly traded national healthcare provider specializing in chronic disease state management (Health Management, Inc.) This parent company of PMA was later acquired by Bergen Brunswig Corporation, now Amerisource Bergen (NYSE: ABC). In 1988, Crosby was the lead co-founder of I.V. Therapy Associates (IVT) and served as Senior Vice President. In January 1991, IVT was acquired by Roberts Pharmaceutical Corporation (AMEX: RPC), which later merged with Shire Pharmaceuticals of London (NASDAQ: SHPGY). From 1985-1987 Crosby established, managed and served as the Director of Pharmacy Services for Charleston Home Therapeutics, Inc. This high-tech pharmacy provided home healthcare patients with intravenous therapy services including intravenous antibiotics, TPN, and intravenous pain management to cancer patients. In the 1980s, Crosby initiated an extensive research effort related to the neurochemistry, neuropharmacology and neurophysiology of pain transmission and the critical involvement of serotonin. Crosby’s work with neuropharmacologic pain management culminated in the development and patenting of a serotonergic combination product used to control severe intractable chronic pain in terminal cancer patients that had developed tolerance to narcotics. Crosby was granted United States and Canadian patents surrounding this product (U.S. Patent #4,698,342 and U.S. Patent # 4,596,807). Crosby received his B.S. Degree in Pharmacy from the Medical University of South Carolina in 1980.

About Zestra Laboratories

Privately held Zestra Laboratories is an innovator in the sexual health products market. Its flagship product—Zestra®—is a natural, topically applied, feminine arousal solution that has demonstrated its ability to increase female arousal, pleasure and satisfaction in Phase II and Phase III-type clinical trials. The company is now leveraging Zestra®’s growing brand recognition and its expertise in pharmacology, transdermal delivery technologies, and women's sexual health research to develop other natural products targeting female and male sexual health that can be sold as a comprehensive product line under the Zestra® brand. Zestra® Feminine Arousal Fluid is a patented, all-natural formulation of two botanical oils and two extracts. It is the only consumer product clinically shown to quickly increase female sexual sensation, arousal, pleasure and desire. Non-prescription Zestra® does not contain potentially harmful synthetics, hormones or parabens.

Zestra®, the result of seven years of research and clinical testing, has shown to be effective in both Phase II-type and Phase III-type, FDA-quality studies for women who have sexual difficulties, including those taking SSRI antidepressants, and to enhance the intimacy experience for women without sexual difficulties. It is available at about 41,000 pharmacies and select supermarkets, including Wal-Mart, Target, CVS, Walgreens, and Rite-Aid. For more information, please visit www.zestra.com/.